



7 February 2020

EXPIRY OF UNLISTED OPTIONS

Zelira Therapeutics Limited (ASX:ZLD, OTCQB: ZLDAF) wishes to advise the of the expiry of the following unlisted options which were not exercised and have therefore lapsed.

Number	Details of Expired Options
4,000,000	Unlisted Options exercisable at \$0.04 on or before 6 February 2020

The Company's current capital structure is as follows:

Number	+Class
874,443,224	Ordinary shares
38,000,000	Unlisted options exercisable at \$0.03125 on or before 17 November 2021.
1,000,000	Unlisted options exercisable at \$0.125 on or before 22 August 2021.
2,000,000	Unlisted options exercisable at \$0.125 on or before 22 August 2021 and subject to vesting conditions.
2,096,667	Unlisted options exercisable at \$0.10 on or before 16 January 2022.
7,500,000	Unlisted options exercisable at \$0.10 on or before 16 January 2022 and subject to vesting conditions.
5,000,000	Unlisted options exercisable at \$0.10 on or before 19 February 2022.
5,000,000	Unlisted options exercisable at \$0.15 on or before 19 February 2022
5,000,000	Unlisted options exercisable at \$0.20 on or before 19 February 2022
5,000,000	Unlisted options exercisable at \$0.28 on or before 19 February 2022 and subject to vesting conditions.
5,000,000	Unlisted options exercisable at \$0.30 on or before 19 February 2022 and subject to vesting conditions.
2,000,000	Unlisted options exercisable at \$0.12 on or before 27 September 2022.
18,750,000	Class A Performance Rights, subject to conversion conditions on or before 28 November 2024
18,750,000	Class B Performance Rights, subject to conversion conditions on or before 28 November 2024
362,620,322	Class A Performance Rights, subject to conversion conditions on or before 2 January 2025
362,620,322	Class B Performance Rights, subject to conversion conditions on or before 2 January 2025

Tim Slate
Company Secretary

About Zelira Therapeutics (www.zeliratx.com)

Zelira Therapeutics Ltd is a leading global therapeutic medicinal cannabis company with access to the world's largest and fastest growing cannabis markets. Zelira owns a portfolio of proprietary revenue generating products and a pipeline of candidates undergoing clinical development that are positioned to enter global markets from 2020. The company is focused on developing branded cannabis products for the treatment of a variety of medical conditions.

The Company is undertaking:

- **Human clinical trial programs** focused on insomnia, autism and opioid reduction with activities in Australia and the USA.
- **Pre-clinical research** examining the effect of cannabinoids in breast, brain and pancreatic cancer as well as research examining the potential for cannabinoids to treat diabetes-associated cognitive decline.

The Company conducts this work in partnership with world-leading researchers and organizations including Complutense University in Madrid, Spain; Curtin University in Perth, Western Australia; the Telethon Kids Institute in Perth; the University of Western Australia, in Perth; St. Vincent's Hospital in Melbourne, Australia; and the Children's Hospital of Philadelphia (CHOP) in the United States.

Zelira has also formed a strategic partnership with European medicinal cannabis group HAPA Pharm BV, to access HAPA Pharm's EU-GMP grade manufacturing capabilities and accessing its German distribution network providing a credible and rapid path to commercialization for successful clinically validated formulations.

The Company has developed two proprietary formulations (HOPE®) already launched and generating revenues in Pennsylvania, has laboratory capabilities to develop formulations in Pennsylvania and Louisiana with ability to conduct clinical trials and is establishing a national footprint across the US for the licensing of its products. The company also has a partnership with Ethicann for the development of a proprietary product, CAN-001, which is being developed for the treatment of chemotherapy-induced nausea and vomiting (CINV), which occurs in approximately 80% of the new 23.6 million cases of cancer annually worldwide.

###

Address

Level 26
140 St Georges Terrace
Perth WA 6000
AUSTRALIA
Tel: +61 8 6558 0886
Fax: +61 8 6316 3337
E: enquiries@zeliratx.com
W: www.zeliratx.com
ACN 103 782 378

Tickers

Australia (ASX): ZLD USA
(OTCQB): ZLDAF

Australia Contact

Dr Richard Hopkins
Managing Director & CEO, Ex USA
+61 405 656 868
rhopkins@zeliratx.com

Monsoon Communications
Rudi Michelson
+61 3 9620 3333
rudim@monsoon.com

USA Contact:

Dr. Oludare Odumosu
Managing Director & CEO, USA
+1-909-855-0675
oodumosu@zeliratx.com
3553 West Chester Pike #110,
Newtown Square, PA 19073
USA

GVM Communications, Inc.
Gia Morón,
347-678-8079 |
gia@gvmcommsinc.com